Developing tests to identify cancer in patients with vague symptoms
Rapid Diagnostic Centre Biomarker Study
Royal Marsden NHS Foundation Trust · NCT05876676
This study is testing new blood and non-blood tests to see if they can quickly identify cancer in people with unclear but worrying symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal Marsden NHS Foundation Trust (other) |
| Locations | 10 sites (Abergavenny and 9 other locations) |
| Trial ID | NCT05876676 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on Rapid Diagnostic Centres (RDCs) in England, which are designed to diagnose patients presenting with non-specific but concerning symptoms of cancer. The study aims to develop a new blood or non-blood test that can quickly identify patients who have cancer or are at higher risk of developing it. By improving the diagnostic process, the study seeks to enhance patient outcomes and streamline cancer screening programs. The research will analyze how vague symptoms relate to underlying health conditions and the effectiveness of RDCs.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years referred to an RDC for suspected cancer investigation.
Not a fit: Patients with a current confirmed diagnosis of active malignancy or those who have been treated for cancer within the last five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier cancer detection and better monitoring for at-risk patients.
How similar studies have performed: While the concept of RDCs is established, the specific approach of developing new diagnostic tests for vague symptoms is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients referred to undergo investigation for suspected cancer within a non-tumour site specific RDC * Age \> 18 years Exclusion Criteria: * Previously treated (treatment completed within 5 years preceding recruitment) * Current confirmed diagnosis of active malignancy * Unable to or unwilling to give informed consent
Where this trial is running
Abergavenny and 9 other locations
- Aneurin Bevan University Local Health Board — Abergavenny, United Kingdom (RECRUITING)
- Glan Clwyd — Bodelwyddan, United Kingdom (RECRUITING)
- Harrogate and District NHS Foundation Trust — Harrogate, United Kingdom (RECRUITING)
- Kingston and Richmond NHS Foundation Trust — Kingston, United Kingdom (RECRUITING)
- Ysbyty Gwynedd — Llandudno, United Kingdom (RECRUITING)
- Chelsea and Westminster Hospital NHS Foundation Trust - Chelsea and Westminster — London, United Kingdom (RECRUITING)
- Chelsea and Westminster Hospital NHS Foundation Trust - West Middlesex — London, United Kingdom (RECRUITING)
- North Middlesex University Hospital NHS Trust — London, United Kingdom (RECRUITING)
- South Tees Hospitals NHS Foundation Trust — Middlesbrough, United Kingdom (RECRUITING)
- Northern Care Alliance NHS Foundation Trust — Salford, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Richard Lee, Dr — Royal Marsden NHS Foundation Trust
- Study coordinator: Serwaa Lashley
- Email: rdcbio@rmh.nhs.uk
- Phone: 020 7808 2603
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer